secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001867096-26-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma reports record Q4 revenue $85.8M (+43% YoY); net income $11.1M, provides FY2026 guidance $375-390M
--------------------------------------------------------------------------------

- Q4 total revenue $85.8M (+42.8% YoY); net income $11.1M vs net loss $5.1M in Q4 2024.
- Recorlev Q4 revenue $45.3M (+100% YoY); FY2025 total revenue $291.8M (+43.7% YoY).
- FY2026 total revenue guidance $375M-$390M, >30% growth at midpoint.
- Adjusted EBITDA Q4 $25.1M, improvement of $16.8M vs prior year.
- Company expects timely execution of XP-8121 Phase 3 trial; remains focused on capital deployment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000012/0001867096-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709626000012/xers-20260302.htm
  HTML page:      https://secwatch.observer/filing/0001867096-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer